Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-03-03
2010-02-23
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07666872
ABSTRACT:
The present invention is concerned with the use of PDE5 inhibitors in medicine.
REFERENCES:
patent: 0 758 653 (1997-02-01), None
patent: 0 985 671 (2000-03-01), None
patent: 1 317 924 (2003-06-01), None
patent: 98/38168 (1998-09-01), None
patent: 01/27112 (2001-04-01), None
patent: 02/089808 (2002-11-01), None
patent: 03/051346 (2003-06-01), None
Wratten, European Journal of Anaesthesiology (2008) 25 (Suppl. 42):1-7.
Wratten, European Journal of Anaesthesiology (2008) 25 (Suppl. 42): 1-7.
Wilson (Neurol. J. Southeast Asia (2003) 8:65-76).
Bischoff (International Journal of Impotence Research (2004) 16:S1-S14).
Ghofrani, H.A., et al., “Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial”,The Lancet, vol. 360, p. 895-900, (2002).
Ghofrani, H.A., et al., “Oral Sildenafil as Long-Term Adjunct Therapy to Inhaled Iloprost in Severe Pulmonary Arterial Hypertension”,Journal of the American College of Cardiology, vol. 42, No. 1, p. 158-164, (2003).
Ghofrani, H.A., et al., “Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension”,Am J Respir Crit Care Med, vol. 167, p. 1139-1141, (2003).
Cunningham, D,R., et al., “The Effects of Chronic Hypoxemia on Central Auditory Processing in Patients with Chronic Obstructive Pulmonary Disease”,Ear and Hearing, vol. 6, No. 6, p. 297-303, (1985).
Bianco, A., et al., “Effect of Sildenafil on Diabetic Gastropathy”,Diabetes Care, vol. 25, No. 10, p. 1188-1889, (2002).
Barnes, P.J., “Cyclic nucleotides and phosphodiesterases and airway function”,Eur Respir J, vol. 8, p. 457-462, (1995).
Halcox, J.P.J., et al., “The Effect of Sildenafil on Human Vascular Function, Platelet Activation, and Myocardial Ischemia”,Journal of American College of Cardiology, vol. 40, No. 7, p. 1232-1240, (2002).
Presberg, K.W., et al., “Pathophysiology of pulmonary hypertension due to lung disease”,Current Opinion in Pulmonary Medicine, vol. 9, p. 131-138, (2003).
Prasad, S., et al., “Sildenafil in Primary Pulmonary Hypertension”,The New Enland Journal of Medicine, vol. 343:1342, No. 18, p. 1-3, (2000).
Nehra, A., et al., “Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications”,World J Urol, vol. 19, p. 40-45, (2001).
Michelakis, E.D., et al., “Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension”,Circulation, vol. 108, p. 2066-2069, (2003).
Kruuse, C., et al., “Migraine can be induced by sildenafil without changes in middle cerebral artery diameter”,Brain, vol. 126, p. 241-247, (2003).
Prickaerts, J., et al., “Effects of Two Selective Phosphodiesterase Type 5 Inhibitors, Sildenafil and Vardenafil, an Object Recognition Memory and Hippocampal Cyclic GMP Levels in the Rat”,Neuroscience, vol. 113, No. 2, p. 351-361, (2002).
Incalzi, R.A., et al., “Cognitive impairment in chronic obstructive pulmonary disease: A neuropsychological and spect study”,J Neurol, vol. 250, p. 325-332, (2003).
Watkins, C.C., et al., “Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy”,The Journal of Clinical Investigation, vol. 106, No. 3, p. 373-384, (2000).
Zhang, R., et al., “Sildenafil (Viagra) Induces Neurogenesis and Promotes Functional Recovery After Stroke in Rats”,Stroke, vol. 33, p. 2675-2680, (2002).
Zhang, R., et al., “Nitric Oxide Enhances Angiogenesis via the Synthesis of Vascular Endothelial Growth Factor and cGMP After Stroke in the Rat”,Circ Res., vol. 92, p. 308-313, (2003).
Yamamoto, T., et al., “Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure”,Clinical Science, vol. 103 (Suppl. 48), p. 2585-2625, (2002).
Reffelmann, T., et al, “Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease”,Circulation, vol. 108, p. 239-244, (2003).
Lehmann et al., Effects of activated protein C on the mesenteric microcirculation and cytokine release during experimental endotoxemia,Can. J. Anesth. 2008, 55:3, pp. 155-162.
Lehmann et al., Activated protein C improves intestinal microcirculation in experimental endotoxaemia in the rat,Critical Care, 2006, 10:R157.
Gupta et al., Activated protein C ameliorates LPS-induced acute kidney injury and down-regulates renal iNOS and angiotensin 2,Am. J. Physiol. Renal Physiol., 2007, Jul. 293(1) F245-54, Epub 2007.
Dunkern Torsten
Ghofrani Hossein Ardeschir
Grimminger Friedrich
Kaps Manfred
Rosengarten Bernhard
Goldberg Joshua B.
Krass Frederick
McGee Sheldon M.
NYCOMED GmbH
Sznaidman Marcos
LandOfFree
Use for PDE5 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use for PDE5 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use for PDE5 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149813